236 related articles for article (PubMed ID: 38415252)
21. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
[TBL] [Abstract][Full Text] [Related]
22. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
[TBL] [Abstract][Full Text] [Related]
23. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract][Full Text] [Related]
24. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
25. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
26. Colorectal Liver Metastasis: Can Cytokines Make the Difference?
Ballarò C; Quaranta V; Giannelli G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001618
[TBL] [Abstract][Full Text] [Related]
27. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update.
Merhi M; Ahmad F; Taib N; Inchakalody V; Uddin S; Shablak A; Dermime S
Semin Cancer Biol; 2023 Feb; 89():1-17. PubMed ID: 36621515
[TBL] [Abstract][Full Text] [Related]
28. The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.
Neupane P; Mimura K; Nakajima S; Okayama H; Ito M; Thar Min AK; Saito K; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Kono K
Anticancer Res; 2021 Oct; 41(10):4895-4905. PubMed ID: 34593437
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Chung BS; Liao IC; Lin PC; Wu SY; Kang JW; Lin BW; Chen PC; Chan RH; Lee CT; Shen MR; Chen SH; Yeh YM
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362062
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
[TBL] [Abstract][Full Text] [Related]
34. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy.
Bhat AA; Nisar S; Singh M; Ashraf B; Masoodi T; Prasad CP; Sharma A; Maacha S; Karedath T; Hashem S; Yasin SB; Bagga P; Reddy R; Frennaux MP; Uddin S; Dhawan P; Haris M; Macha MA
Cancer Commun (Lond); 2022 Aug; 42(8):689-715. PubMed ID: 35791509
[TBL] [Abstract][Full Text] [Related]
35. Exosomes in tumor-stroma crosstalk: Shaping the immune microenvironment in colorectal cancer.
Zhang Y; Huo M; Li W; Zhang H; Liu Q; Jiang J; Fu Y; Huang C
FASEB J; 2024 Mar; 38(6):e23548. PubMed ID: 38491832
[TBL] [Abstract][Full Text] [Related]
36. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
37. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches.
Zafari N; Khosravi F; Rezaee Z; Esfandyari S; Bahiraei M; Bahramy A; Ferns GA; Avan A
J Clin Lab Anal; 2022 Aug; 36(8):e24585. PubMed ID: 35808903
[TBL] [Abstract][Full Text] [Related]
38. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L
Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738
[TBL] [Abstract][Full Text] [Related]
39. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
Shan J; Han D; Shen C; Lei Q; Zhang Y
Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
[TBL] [Abstract][Full Text] [Related]
40. Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.
Kotsifaki A; Alevizopoulos N; Dimopoulou V; Armakolas A
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
